Study in human cells shows it counteracts Ebola’s defenses
Amid the worsening Ebola outbreak in the Congo, now threatening to spill into Rwanda, a new study suggests that an existing, FDA-approved drug called nitazoxanide could potentially help contain this deadly, highly contagious infection. In meticulous experiments in human cells, led by Boston Children’s Hospital, the drug significantly amplified immune responses to Ebola and inhibited Ebola replication.
The study, published in the Cell Press journal iScience, also showed how the drug works: It enhances the immune system’s ability to detect Ebola, normally impeded by the virus.
Nitazoxanide, or NTZ, is currently used to treat gastrointestinal infections caused by parasites such as Giardia and Cryptosporidium. It has been shown to be safe and even comes in a formulation for children. Study leader Anne Goldfeld, MD, of the Program in Cellular and Molecular Medicine at Boston Children’s, hopes that, with further testing and validation, it could be part of the solution for Ebola.
“Currently, there is no easily deployable therapy for Ebola virus,” she says. “There are some very promising vaccines, but there is no oral, inexpensive medication available.”
The Ebola virus caused more than 10,000 deaths in the 2014-2016 West African epidemic and more than 1,800 lives (as of August 6th) in the current outbreak in the Democratic Republic of the Congo. The virus is very good at evading human immune defenses. Though very small, it has two genes devoted to blocking immune responses.
Goldfeld and collaborators Chad Mire, PhD and Thomas Geisbert, PhD at the University of Texas Medical Branch, Galveston, showed in Biosafety Level 4 laboratory experiments that NTZ inhibits the Ebola virus (isolated from an earlier outbreak). Additional experiments performed in collaboration with Sun Hur, PhD of Boston Children’s showed that NTZ works by broadly amplifying the interferon pathway and cellular viral sensors, including two known as RIG-I and PKR. By deleting RIG-I and PKR in human cells through CRISPR editing, Goldfeld and University of Texas colleagues showed that NTZ works through these molecules to inhibit Ebola virus.
“Ebola masks RIG-I and PKR, so that cells don’t perceive that Ebola is inside,” explains Goldfeld. “This lets Ebola get a foothold in the cell and race ahead of the immune response. What we’ve been able to do is enhance the host viral detection response with NTZ. It’s a new path in treating Ebola.”
Goldfeld hopes to move into animal studies soon, especially given that NTZ has already been used in millions of people with minimal side effects. If effective, it could thus be easily repurposed for Ebola treatment or prevention.
The Latest on: Ebola
via Google News
The Latest on: Ebola
- Stopping Ebola on November 18, 2019 at 10:17 am
A new vaccine may help turn Ebola into a disease we can prevent, and a new drug may make it one we can cure. But the political crisis in the Democratic Republic of Congo has fueled violence against ...
- What it takes to protect gorillas from Ebola on November 18, 2019 at 3:42 am
It’s possible that as much as a third of the global Western lowland gorilla population, a critically endangered subspecies, was wiped out by Ebola in the early 2000s, experts say. Now mountain ...
- Ebola Virus Vaccine Approved Worldwide, Saves Hundreds Of Thousands Of Lives on November 18, 2019 at 3:40 am
This came to light as the health body verified that the treatment is safe for use worldwide. This made it the first Ebola vaccine certified to protect thousands of individuals who are 18 years old or ...
- Ebola Vaccine Market In-depth Analysis and Detailed Survey by 2026 on November 17, 2019 at 9:07 pm
rVSV-ZEBOV uses strain of Zaire Ebola virus. Merck is planning to file for final marketing approval of its EVD vaccine with the U.S. FDA in 2018. Moreover, it produced 3,00,000 vaccines, in case of ...
- Can local and faith leaders help halt the spread of Ebola in DRC? on November 17, 2019 at 3:38 am
Political, security and cultural complications have made it difficult for health workers in the Democratic Republic of Congo to contain an Ebola outbreak that has killed at least 2000 people since it ...
- Troopers detained Liberian official buying drugs for Ebola. Judge says they got it wrong. on November 16, 2019 at 9:00 am
Now, five years later, a federal judge in New Jersey has ruled that state troopers improperly detained the official and his friend several years ago, as part of a unique racial profiling lawsuit that ...
- Congo’s president hopes Ebola outbreak will end this year on November 15, 2019 at 1:27 pm
Congo's President Felix Tshisekedi says he’s hopeful the Ebola outbreak in his country will end in the coming weeks. Tshisekedi said Friday a few cases of the deadly contagious disease remain in the ...
- Congo president says Ebola outbreak should be over this year on November 15, 2019 at 8:10 am
BERLIN (Reuters) - An outbreak of Ebola in eastern Democratic Republic of Congo should be eradicated by the end of 2019, Congolese President Felix Tshisekedi said on Friday. The epidemic in Congo was ...
- Finally, An Ebola Vaccine on November 14, 2019 at 9:13 pm
The EU has approved an Ebola vaccine. Credit: UC Rusal Photo Gallery/CC BY 2.0 Christopher Intagliata is Science Friday’s senior producer. He once served as a prop in an optical illusion and speaks ...
- At Ebola ground zero in DR Congo, new vaccine offers hope on November 14, 2019 at 10:17 am
Beni, Democratic Republic of Congo - This city in northeastern DRC has been on a high Ebola alert for nearly a year and a half since the latest outbreak started, killing more than 2,000 people.
via Bing News